770 related articles for article (PubMed ID: 31857304)
1. Association of brain amyloidosis with the incidence and frequency of neuropsychiatric symptoms in ADNI: a multisite observational cohort study.
Goukasian N; Hwang KS; Romero T; Grotts J; Do TM; Groh JR; Bateman DR; Apostolova LG
BMJ Open; 2019 Dec; 9(12):e031947. PubMed ID: 31857304
[TBL] [Abstract][Full Text] [Related]
2. Neuropsychiatric symptoms and brain morphology in patients with mild cognitive impairment and Alzheimer's disease with dementia.
Siafarikas N; Alnæs D; Monereo-Sanchez J; Lund MJ; Selbaek G; Stylianou-Korsnes M; Persson K; Barca ML; Almdahl IS; Fladby T; Aarsland D; Andreassen OA; Westlye LT
Int Psychogeriatr; 2021 Nov; 33(11):1217-1228. PubMed ID: 34399870
[TBL] [Abstract][Full Text] [Related]
3. Serotonin Selective Reuptake Inhibitor Treatment Improves Cognition and Grey Matter Atrophy but not Amyloid Burden During Two-Year Follow-Up in Mild Cognitive Impairment and Alzheimer's Disease Patients with Depressive Symptoms.
Brendel M; Sauerbeck J; Greven S; Kotz S; Scheiwein F; Blautzik J; Delker A; Pogarell O; Ishii K; Bartenstein P; Rominger A;
J Alzheimers Dis; 2018; 65(3):793-806. PubMed ID: 30010116
[TBL] [Abstract][Full Text] [Related]
4. Neuropsychiatric Symptoms and Risk of Progression to Alzheimer's Disease Among Mild Cognitive Impairment Subjects.
Dietlin S; Soto M; Kiyasova V; Pueyo M; de Mauleon A; Delrieu J; Ousset PJ; Vellas B
J Alzheimers Dis; 2019; 70(1):25-34. PubMed ID: 31127783
[TBL] [Abstract][Full Text] [Related]
5. Frequency and subgroups of neuropsychiatric symptoms in mild cognitive impairment and different stages of dementia in Alzheimer's disease.
Siafarikas N; Selbaek G; Fladby T; Šaltytė Benth J; Auning E; Aarsland D
Int Psychogeriatr; 2018 Jan; 30(1):103-113. PubMed ID: 28927477
[TBL] [Abstract][Full Text] [Related]
6. The impact of subthreshold levels of amyloid deposition on conversion to dementia in patients with amyloid-negative amnestic mild cognitive impairment.
Kim HJ; Oh JS; Lim JS; Lee S; Jo S; Chung EN; Shim WH; Oh M; Kim JS; Roh JH; Lee JH;
Alzheimers Res Ther; 2022 Jul; 14(1):93. PubMed ID: 35821150
[TBL] [Abstract][Full Text] [Related]
7. Cortical β-amyloid burden, neuropsychiatric symptoms, and cognitive status: the Mayo Clinic Study of Aging.
Krell-Roesch J; Vassilaki M; Mielke MM; Kremers WK; Lowe VJ; Vemuri P; Machulda MM; Christianson TJ; Syrjanen JA; Stokin GB; Butler LM; Traber M; Jack CR; Knopman DS; Roberts RO; Petersen RC; Geda YE
Transl Psychiatry; 2019 Mar; 9(1):123. PubMed ID: 30923322
[TBL] [Abstract][Full Text] [Related]
8. Neuropsychiatric symptoms and global functional impairment along the Alzheimer's continuum.
Wadsworth LP; Lorius N; Donovan NJ; Locascio JJ; Rentz DM; Johnson KA; Sperling RA; Marshall GA
Dement Geriatr Cogn Disord; 2012; 34(2):96-111. PubMed ID: 22922821
[TBL] [Abstract][Full Text] [Related]
9. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
[TBL] [Abstract][Full Text] [Related]
10. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.
Doraiswamy PM; Sperling RA; Coleman RE; Johnson KA; Reiman EM; Davis MD; Grundman M; Sabbagh MN; Sadowsky CH; Fleisher AS; Carpenter A; Clark CM; Joshi AD; Mintun MA; Skovronsky DM; Pontecorvo MJ;
Neurology; 2012 Oct; 79(16):1636-44. PubMed ID: 22786606
[TBL] [Abstract][Full Text] [Related]
11. An Exploration of Subgroups of Neuropsychiatric Symptoms in Mild Cognitive Impairment and Their Risks of Conversion to Dementia or Death.
Qiu J; Goldstein FC; Hanfelt JJ
Am J Geriatr Psychiatry; 2022 Aug; 30(8):925-934. PubMed ID: 35067420
[TBL] [Abstract][Full Text] [Related]
12. Apathy as a feature of prodromal Alzheimer's disease: an FDG-PET ADNI study.
Delrieu J; Desmidt T; Camus V; Sourdet S; Boutoleau-Bretonnière C; Mullin E; Vellas B; Payoux P; Lebouvier T;
Int J Geriatr Psychiatry; 2015 May; 30(5):470-7. PubMed ID: 24953008
[TBL] [Abstract][Full Text] [Related]
13. Associations between Neuropsychiatric Symptoms and Cerebral Amyloid Deposition in Cognitively Impaired Elderly People.
Bensamoun D; Guignard R; Furst AJ; Derreumaux A; Manera V; Darcourt J; Benoit M; Robert PH; David R
J Alzheimers Dis; 2016; 49(2):387-98. PubMed ID: 26484900
[TBL] [Abstract][Full Text] [Related]
14. Neuropsychiatric symptoms differently affect mild cognitive impairment and Alzheimer's disease patients: a retrospective observational study.
Scaricamazza E; Colonna I; Sancesario GM; Assogna F; Orfei MD; Franchini F; Sancesario G; Mercuri NB; Liguori C
Neurol Sci; 2019 Jul; 40(7):1377-1382. PubMed ID: 30903419
[TBL] [Abstract][Full Text] [Related]
15. Effect of Education on Alzheimer's Disease-Related Neuroimaging Biomarkers in Healthy Controls, and Participants with Mild Cognitive Impairment and Alzheimer's Disease: A Cross-Sectional Study.
Wada M; Noda Y; Shinagawa S; Chung JK; Sawada K; Ogyu K; Tarumi R; Tsugawa S; Miyazaki T; Yamagata B; Graff-Guerrero A; Mimura M; Nakajima S;
J Alzheimers Dis; 2018; 63(2):861-869. PubMed ID: 29689728
[TBL] [Abstract][Full Text] [Related]
16. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of neuropsychiatric symptoms in mild cognitive impairment and Alzheimer's disease, and its relationship with cognitive impairment.
M FM; Molano A; Castro J; Zarranz JJ
Curr Alzheimer Res; 2010 Sep; 7(6):517-26. PubMed ID: 20455862
[TBL] [Abstract][Full Text] [Related]
18. Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment.
Ramakers IH; Verhey FR; Scheltens P; Hampel H; Soininen H; Aalten P; Rikkert MO; Verbeek MM; Spiru L; Blennow K; Trojanowski JQ; Shaw LM; Visser PJ;
Psychol Med; 2013 May; 43(5):911-20. PubMed ID: 22954311
[TBL] [Abstract][Full Text] [Related]
19. The Association Between Biomarkers and Neuropsychiatric Symptoms Across the Alzheimer's Disease Spectrum.
Banning LCP; Ramakers IHGB; Köhler S; Bron EE; Verhey FRJ; de Deyn PP; Claassen JAHR; Koek HL; Middelkoop HAM; van der Flier WM; van der Lugt A; Aalten P; ;
Am J Geriatr Psychiatry; 2020 Jul; 28(7):735-744. PubMed ID: 32088096
[TBL] [Abstract][Full Text] [Related]
20. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
